Shattuck Labs Q3 net loss $16.7M; shifts focus to SL-325 DR3 antibody; cash runway into 2027

Shattuck Labs, Inc.

2024-Q3 EPS reported -$1.12 revenue$5,721,000

Net loss of $16.7M ($0.33 per share) vs $27.5M in Q3 2023; no revenue (pre-revenue stage).
Strategic pivot: discontinuing SL-172154; prioritizing first-in-class DR3 antagonist SL-325 with IND filing expected Q3 2025.
Cash and investments ~$90.1M as of Sept 30, 2024, expected to fund operations into 2027.
Substantially completed restructuring (workforce reduction) tied to SL-172154 discontinuation.
R&D expenses fell to $16.3M from $24.2M; G&A expenses dropped to $4.6M from $5.1M YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.